Neurocrine Biosciences Starts Phase 3 Trial of Osavampator for MDD

Neurocrine Biosciences, Inc., a leading neuroscience-focused, biopharmaceutical company, announced the initiation of a phase 3 registrational study to evaluate the efficacy, safety and tolerability of osavampator (formerly NBI-1065845), an investigational drug under development as an adjunctive treatment to antidepressants for major depressive disorder (MDD). Positive topline data for the phase 2 SAVITRI study of osavampator in adult subjects with MDD were announced in April 2024.

""Osavampator has the potential to become a first-in-class treatment for MDD, a disorder that impacts more than 21 million people in the United States,"" said Eiry W. Roberts, M.D., chief medical officer at Neurocrine Biosciences. ""More than a third of those MDD sufferers endure debilitating symptoms that current treatment options cannot fully resolve.""

The phase 2 SAVITRI study with osavampator met its primary and secondary endpoints, and was generally well tolerated.

""Major depressive disorder is a condition that has a profound effect on patients and their families and is associated with significant morbidity and mortality,"" said Maurizio Fava, M.D., Chair, Mass General Brigham Academic Medical Centers Department of Psychiatry. ""The great majority of patients suffering from major depressive disorder do not achieve a sustained remission of their condition and the options for next step strategies to help them are quite limited. This trial is happening at a time when it is clear that, as a field, we need to develop new augmentation strategies to enhance the efficacy of standard antidepressants.""

Osavampator (formerly NBI-1065845) is a potential first-in-class, investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) positive allosteric modulator (PAM) in development as a potential treatment for patients with inadequate response to treatment in MDD. Neurocrine received an exclusive license to osavampator from Takeda Pharmaceutical Company Limited for all indications in all territories worldwide except Japan.

The phase 3 registrational program is designed to assess the efficacy, safety and tolerability of osavampator in adult subjects with MDD. The study will enroll adults with a primary diagnosis of MDD, who have inadequate response to current antidepressant treatment. For more information about the phase 3 osavampator study, click here.

Major depressive disorder (MDD) is a serious disorder characterized by a persistently depressed mood, loss of interest, poor concentration, and decreased energy, among other symptoms. According to the World Health Organization, MDD is one of the leading causes of disability, is a serious condition that presents an increased risk of suicide and self-harm, and is associated with increased all-cause mortality rates. More than 21 million people in the US live with MDD and it is estimated that roughly a third of those do not respond to available antidepressants.

Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!